Treatment of osteoporosis in men

Calcified Tissue International

Volumn 75, Issue 2, 2004, Pages 114-119

  Orwoll, E S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTRADIOL; FLUORIDE; GLUCOCORTICOID; GONADORELIN AGONIST; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D;

BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HYPOGONADISM; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT INDICATION;

BONE AND BONES; BONE DENSITY; DIPHOSPHONATES; GONADAL STEROID HORMONES; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; PATIENT SELECTION; SEX CHARACTERISTICS;

EID: 4444247699     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-004-0288-5     Document Type: Conference Paper

References (26)

1. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
2. Ringe ID, Faber H, Dorst A (2001) Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 86:5252-5255
3. Weber TJ, Drezner MK (2001) Effect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism 50:912-915
4. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73:133-139
5. Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11:98-101
6. Miller P, Orwoll E, MacIntyre B, Smith M, Vandormeal K, Leung A (2003) Treatment with alendronate 70 mg once weekly for 12 months increases BMD and decreases biochemical markers of bone turnover in men with osteoporosis. Second International Conference on Osteoporosis in Men, Genoa, Italy
7. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp A, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044-1052
8. Ringe JD, Orwoll E, Daifotis A, Lombardi A (2002) Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 13:195-199
9. Ringe JD, Dorst A, Faber H (2003) Risedronate reduces vertebral fractures in men with osteoporosis. J Bone Miner Res 18:S160
10. Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily residronate in the treatment of corticosteroid-induced osteoporosis in men and women. A J Bone Miner Res 15:1006-1013
11. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
12. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice M-P, Czachur M, Diafotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
13. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PEE, Hawkens F, Correa-Rotter R, Menkes C, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite M, Siminoski KG, Nevitt MC, Sharp JT, Malice M, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum 44:202-211
14. Smith MR, McGovern FJ, Zietman AL, Fallen MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
15. Kurland ES, Cosman F, McMahon DJ, Rosen C, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
16. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [Human Parathyroid Hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
17. Orwoll ES, Scheele WH, Clancy AD, Adami S, Syversen U, Kaufman JM (2001) Recombinant human parathyroid hormone (1-34) increases bone mineral density in men with both idopathic and hypogonadal osteoporosis. Arthritis Rheum 44:S379.
18. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633
19. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386-2390
20. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS (1996) Testosterone replacement therapy improves mood in hypogonadal men-A clinical research center study. J Clin Endocrinol Metab 81:3578-3583
21. Snyder PJ, Peachey H, Hannoush P, Berline JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972
22. Bilezikian JP, Morishima A, Bell J, Grumbach MM (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603
23. Khosla S, Melton J III, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443-1450
24. Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setniker I (1998) Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporos Int 8:47-52
25. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Eng J Med 349:1216-1226
26. Armory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto A, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increase in bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:501-502